Effectiveness of dapagliflozin on vascular endothelial function and glycemic control in patients with early-stage type 2 diabetes mellitus: DEFENCE study.
Fumika ShigiyamaNaoki KumashiroMasahiko MiyagiKayoko IkeharaEiichiro KandaHiroshi UchinoTakahisa HirosePublished in: Cardiovascular diabetology (2017)
Dapagliflozin add-on therapy to metformin for 16 weeks improved endothelial function, as assessed by FMD, in patients with inadequately controlled early-stage T2DM. Improvement in oxidative stress may contribute to the improvement in FMD. Trial registration University Hospital Medical Information Network Clinical Trial Registry (UMIN000018754).
Keyphrases
- glycemic control
- early stage
- type diabetes
- clinical trial
- blood glucose
- oxidative stress
- study protocol
- phase ii
- weight loss
- phase iii
- randomized controlled trial
- sentinel lymph node
- systematic review
- insulin resistance
- healthcare
- open label
- dna damage
- cardiovascular disease
- metabolic syndrome
- health information
- gestational age
- induced apoptosis
- bone marrow
- neoadjuvant chemotherapy